家族性孤立性甲状旁腺功能亢进症的新概念
本文综述家族性孤立性甲状旁腺功能亢进症(FIHP)的新概念,其定义为不伴其他复杂甲状旁腺综合征特征性腺外表现的家族性原发性甲状旁腺功能亢进症。当前概念涵盖MEN1、CASR、CDC73等基因突变的不完全表达,最新关注点为无这些基因突变的家系,其中17%存在GCM2种系激活突变。
要点
- FIHP定义为不伴复杂综合征腺外特征的家族性原发性甲状旁腺功能亢进症。
- 当前FIHP概念可包括MEN1、CASR、CDC73突变或相关综合征的不完全表达。
- 无MEN1、CASR、CDC73突变的家系中17%有GCM2种系激活突变。
核心结论
- 当前FIHP概念聚焦于无MEN1、CASR或CDC73突变的小家系,有助于发现17%家系存在GCM2种系激活突变。
- 尚需更多病例的临床与突变特征分析以确定伴或不伴GCM2突变的FIHP是否有独特临床特征。
研究设计与样本
- 通过PubMed检索FIHP、其他家族性甲状旁腺功能亢进综合征及各自突变基因的文献进行综述。
主要发现
- 最新FIHP概念关注无MEN1、CASR或CDC73基因突变的家系,其中17%具有GCM2转录因子基因的种系激活突变。
- 伴或不伴GCM2突变的FIHP家系中原发性甲状旁腺功能亢进症病例数中位数仅为2例。
- 两个FIHP亚组家系规模小可能源于亲属筛查率低。
- 伴GCM2突变的FIHP患者成年起病,表现为轻度高钙血症和多发性甲状旁腺肿瘤。
局限性
- FIHP因家系小和病例症状轻微而难以研究。
- 需更多病例的临床与突变特征分析以明确FIHP的独特临床特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Familial isolated hyperparathyroidism (FIHP) is defined as familial primary hyperparathyroidism (FH) without a characteristic extraparathyroidal feature of a more complex hyperparathyroid syndrome. New concepts of FIHP have been developed within this definition. FIHP has been difficult to study due to small kindreds and mildly symptomatic cases. EVIDENCE ACQUISITION: Searches were through PubMed for FIHP, other FH syndromes, and the gene(s) mutated in each. EVIDENCE SYNTHESIS: Within its definition, the current concept of FIHP has clinical and mutational components that can include incomplete expressions of multiple endocrine neoplasia type 1 (MEN1) familial hypocalciuric hypercalcemia, hyperparathyroidism-jaw tumor syndromes, or their mutations. Newest concepts of FIHP focus on kindreds without mutation of the MEN1, CASR, or CDC73 genes; 17% have germline activating mutation of the gene for the GCM2 transcription factor. The FIHP kindreds with or without GCM2 mutation contain a median of only two cases of primary hyperparathyroidism. The small kindred size in both subgroups of FIHP is probably caused by a low rate of screening among relatives. Persons with FIHP and GCM2 mutation present as adults with mild hypercalcemia and multiple parathyroid tumors. CONCLUSION: The current concept of FIHP led to a focus on small kindreds without mutation of MEN1, CASR, or CDC73. These assisted in identifying germline activating GCM2 mutations in 17% of kindreds. Clinical and mutational characterization in more cases is needed to determine if there are any unique clinical features of FIHP, with or without mutation of GCM2.
引用
- Marx SJ. New Concepts About Familial Isolated Hyperparathyroidism. J Clin Endocrinol Metab. 2019. PMID: 30848815. doi:10.1210/jc.2018-02789
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。